Michael Gelband’s Citius Pharmaceuticals CTXR Stock Holding History

Michael Gelband’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,220	Closed	-$55K	–	2018
2022 Q1	$55K	Sell	1,220 -785	-39%	-$31K	﹤0.01%	2056
2021 Q4	$77K	Buy	+2,005	New	+$91K	﹤0.01%	1987

Other funds holding CTXR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Michael Gelband's CTXR Position: Q2 2022 in Review

Michael Gelband sold out of Citius Pharmaceuticals (CTXR) in Q2 2022, closing a stake of 1,220 shares — an estimated $55K sold.

Michael Gelband first reported a position in CTXR in Q4 2021 and held it in 2 quarters. The position peaked at $77K in Q4 2021. 60 funds tracked by Wall St. Rank hold CTXR as of Q2 2022.

Michael Gelband reported no remaining Citius Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Michael Gelband sold 1,220 Citius Pharmaceuticals shares in Q2 2022, an estimated $55K.
Michael Gelband first reported a position in Citius Pharmaceuticals in Q4 2021 and held it in 2 quarters.
Michael Gelband's Citius Pharmaceuticals position peaked at $77K in Q4 2021.
60 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.